Tackling TED at the site of pathology.
Thyroid Eye Disease
KRIYA.586 is a one-time investigational gene therapy designed to inhibit IGF1R, with the goal of improving the clinical manifestations of thyroid eye disease, including proptosis and diplopia.
Thyroid eye disease (TED) is an autoimmune disease characterized by inflammation of the extraocular muscles, orbital fat, and surrounding connective tissue. As it worsens, it can cause proptosis (bulging of the eyes) and diplopia (double vision) among other issues.
KRIYA.586
How it works
In TED, Insulin Growth Factor 1 Receptor (IGF1R) signaling drives inflammation and tissue expansion behind the eye, causing swelling and vision disturbances. KRIYA.586 is designed to express an anti-IGF1R antibody locally in the tissue around the eye to block IGF1R signaling at the site of pathology and provide durable inhibition from a single in-office injection.
Loading…
Failed to load vial.
Specifications
| Modality | AAV-based gene therapy |
|---|---|
| Mechanism | IGF1R inhibition |
| Payload | Anti-IGF1R antibody |
| Delivery | Peribulbar injection, outpatient |
| Dosing frequency | Single administration |
| Potential patient impact | ~1 million, US and EU |
| Stage | Phase 1/2 |
Disclaimer
Kriya’s durable medicines are investigational and have not been approved as safe or effective by any regulatory health authority.
